Skip Navigation

Home > UK Clinical guidelines for use of depot buprenorphine (Buvidal®) in the treatment of opioid dependence.

Halliday, Kate, ed. Lintzeris, Nicholas and Dunlop, Adrian and Finch, Emily and Parsons, Graham and Hard, Bernadette and Brinksman, Steve . (2020) UK Clinical guidelines for use of depot buprenorphine (Buvidal®) in the treatment of opioid dependence. London: SMMGP. 54 p.

[img]
Preview
PDF (UK Clinical guidelines for use of depot buprenorphine)
992kB

This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long-acting injected buprenorphine preparations.

Buvidal® is a prolonged-release formulation of buprenorphine (BPN), registered in the UK for ‘Treatment of opioid dependence within a framework of medical, social and psychological treatment’. Treatment is intended for use in adults and adolescents aged 16 years or over. Buvidal® is designed to be administered by subcutaneous injection once a week or once a month.


Repository Staff Only: item control page